Experience of targeted therapy for ALK positive non-small cell lung cancer – a clinical case

Lung cancer holds a leading position in the cancer mortality pattern worldwide. The emergence of knowledge about driver mutations heralded a new era in the targeted therapy for lung carcinomas. ALK translocation is identified in 5–7% of non-small cell lung cancer cases. ALK-positive lung adenocarcin...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: A. V. Sultanbaev, Sh. I. Musin, K. V. Menshikov, A. F. Nasretdinov, B. A. Ibragimov, A. G. Nigmatullin, R. T. Ayupov, A. A. Izmailov, N. I. Sultanbaeva
Formato: Artigo
Idioma:Russo
Publicado em: Remedium Group LLC 2020-12-01
Colecção:Медицинский совет
Assuntos:
non-small cell lung cancer
adenocarcinoma
alk translocation
alk inhibitors
alectinib
progression-free survival
Acesso em linha:https://www.med-sovet.pro/jour/article/view/5954
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados